Risk of bleeding in cancer patients treated with the angiogenesis inhibitor bevacizumab: A meta-analysis

被引：0
|
作者：
Sher, A. F. [1 ]
Chu, D. [1 ]
Wu, S. [1 ]
机构：
[1] Stony Brook Univ Hosp, Stony Brook, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9584,34
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients A Meta-analysis
    Nalluri, Shobha Rani
    Chu, David
    Keresztes, Roger
    Zhu, Xiaolei
    Wu, Shenhong
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 300 (19): : 2277 - 2285
  • [2] Effect of Angiogenesis Inhibitor Bevacizumab on Survival in Patients with Cancer: A Meta-Analysis of the Published Literature
    Su, Yuan
    Yang, Wei-Bing
    Li, Shi
    Ye, Zhi-Jian
    Shi, Huan-Zhong
    Zhou, Qiong
    [J]. PLOS ONE, 2012, 7 (04):
  • [3] Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis
    Hapani, Sanjaykumar
    Chu, David
    Wu, Shenhong
    [J]. LANCET ONCOLOGY, 2009, 10 (06): : 559 - 568
  • [4] Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials
    Hang, Xiao Feng
    Xu, Wen Sheng
    Wang, Jun Xue
    Wang, Lei
    Xin, Hai Guang
    Zhang, Rui Qi
    Ni, Wu
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 67 (06) : 613 - 623
  • [5] Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials
    Xiao Feng Hang
    Wen Sheng Xu
    Jun Xue Wang
    Lei Wang
    Hai Guang Xin
    Rui Qi Zhang
    Wu Ni
    [J]. European Journal of Clinical Pharmacology, 2011, 67 : 613 - 623
  • [6] Risk of Serious Neutropenic Events in Cancer Patients Treated with Bevacizumab: A Meta-analysis
    Zhou, Fan
    Shao, Jiang-Hua
    Wu, Lin-Quan
    Yin, Xiang-Bao
    Yu, Xin
    [J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (04) : 2453 - 2459
  • [7] Increased Risk of Cerebrovascular Events in Patients with Cancer Treated with Bevacizumab: A Meta-Analysis
    Zuo, Pei-Yuan
    Chen, Xing-Lin
    Liu, Yu-Wei
    Xiao, Chang-Liang
    Liu, Cheng-Yun
    [J]. PLOS ONE, 2014, 9 (07):
  • [8] Risk of Bleeding in Hepatocellular Carcinoma Patients Treated with Atezolizumab/Bevacizumab: A Systematic Review and Meta-Analysis
    Song, Young-Gi
    Yeom, Kyeong-Min
    Jung, Eun Ae
    Kim, Sang Gyune
    Kim, Young Seok
    Yoo, Jeong-Ju
    [J]. LIVER CANCER, 2024,
  • [9] Bleeding risk with bevacizumab - meta-analysis findings
    [J]. Reactions Weekly, 2011, 1345 (1) : 4 - 4
  • [10] Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials
    Ranpura, Vishal
    Hapani, Sanjaykumar
    Chuang, Jeff
    Wu, Shenhong
    [J]. ACTA ONCOLOGICA, 2010, 49 (03) : 287 - 297
12345